Open-label pilot study of interferon gamma-1b in Friedreich ataxia
Authors:
- 21 October 2014
- journal article
- clinical trial
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 132 (1) , 7-15
Abstract
Objectives/Aims This is an open‐label trial of the safety of interferon gamma‐1b (IFN‐γ) and its effect on frataxin levels and neurologic measures in 12 children with Friedreich ataxia. Materials and Methods Interferon gamma‐1b was administered via subcutaneous injection three times weekly. The dose increased from 10 to 50 mcg/m2 during the first four weeks and then remained at 50 mcg/m2 for final eight weeks. Safety assessments included laboratory testing, electrocardiogram, and monitoring of adverse events. The primary efficacy outcome measure was frataxin level in whole blood. Secondary measures included frataxin levels in multiple tissues, frataxin mRNA levels, Friedreich Ataxia Rating Scale (FARS) scores and other neurologic evaluations. Statistical analyses were performed via SAS and STATA. Results Interferon gamma‐1b was well tolerated with no serious adverse events, and only two subjects reporting severe adverse events and subsequent dose reductions. Small but significant changes in frataxin levels were observed in red blood cells, PBMC, and platelets after 12 weeks of treatment. However, the magnitude of change was small and varied between tissues. Mean improvement in FARS score was equivalent to roughly 18 months of disease progression after 12 weeks of treatment (P = 0.008). No other statistically significant changes were observed. No statistically significant relationships were observed between frataxin protein levels, FARS scores, and in vivo IFN‐γ levels. Conclusions Interferon gamma‐1b improved FARS scores without a clear relationship to changes in frataxin levels. Larger, longer placebo‐controlled trials including biochemical assessments in affected tissues are necessary to evaluate fully the efficacy and utility of IFN‐γ in FRDA.Keywords
Funding Information
- Friedreich Ataxia Research Alliance
This publication has 21 references indexed in Scilit:
- Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trialActa Neurologica Scandinavica, 2013
- A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trialMovement Disorders, 2012
- Friedreich's ataxia: Pathology, pathogenesis, and molecular geneticsJournal of the Neurological Sciences, 2011
- A rapid, noninvasive immunoassay for frataxin: Utility in assessment of Friedreich ataxiaMolecular Genetics and Metabolism, 2010
- A Phase 3, Double-blind, Placebo-Controlled Trial of Idebenone in Friedreich AtaxiaArchives of Neurology, 2010
- Friedreich Ataxia Mouse Models with Progressive Cerebellar and Sensory Ataxia Reveal Autophagic Neurodegeneration in Dorsal Root GangliaThe Journal of Neuroscience, 2004
- Friedreich AtaxiaArchives of Neurology, 2002
- Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxiaNature Genetics, 1997
- Regulation of Mitochondrial Iron Accumulation by Yfh1p, a Putative Homolog of FrataxinScience, 1997
- FRIEDREICH'S ATAXIA: A CLINICAL AND GENETIC STUDY OF 90 FAMILIES WITH AN ANALYSIS OF EARLY DIAGNOSTIC CRITERIA AND INTRAFAMILIAL CLUSTERING OF CLINICAL FEATURESBrain, 1981